[go: up one dir, main page]

AU2003254129A1 - Method and composition for treating and preventing hepatitis b infection and symptoms thereof - Google Patents

Method and composition for treating and preventing hepatitis b infection and symptoms thereof

Info

Publication number
AU2003254129A1
AU2003254129A1 AU2003254129A AU2003254129A AU2003254129A1 AU 2003254129 A1 AU2003254129 A1 AU 2003254129A1 AU 2003254129 A AU2003254129 A AU 2003254129A AU 2003254129 A AU2003254129 A AU 2003254129A AU 2003254129 A1 AU2003254129 A1 AU 2003254129A1
Authority
AU
Australia
Prior art keywords
symptoms
infection
treating
composition
preventing hepatitis
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2003254129A
Other versions
AU2003254129A8 (en
Inventor
Adrian Hobden
Scott Morham
Kenton Zavitz
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Myriad Genetics Inc
Original Assignee
Myriad Genetics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Myriad Genetics Inc filed Critical Myriad Genetics Inc
Publication of AU2003254129A1 publication Critical patent/AU2003254129A1/en
Publication of AU2003254129A8 publication Critical patent/AU2003254129A8/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/29—Hepatitis virus
    • A61K39/292—Serum hepatitis virus, hepatitis B virus, e.g. Australia antigen
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/93—Ligases (6)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5156—Animal cells expressing foreign proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/10—Fusion polypeptide containing a localisation/targetting motif containing a tag for extracellular membrane crossing, e.g. TAT or VP22
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10161—Methods of inactivation or attenuation

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Microbiology (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Mycology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Biotechnology (AREA)
  • Communicable Diseases (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
AU2003254129A 2002-07-19 2003-07-21 Method and composition for treating and preventing hepatitis b infection and symptoms thereof Abandoned AU2003254129A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US39705402P 2002-07-19 2002-07-19
US60/397,054 2002-07-19
US45302803P 2003-03-07 2003-03-07
US60/453,028 2003-03-07
PCT/US2003/022961 WO2004009032A2 (en) 2002-07-19 2003-07-21 Method and composition for treating and preventing hepatitis b infection and symptoms thereof

Publications (2)

Publication Number Publication Date
AU2003254129A1 true AU2003254129A1 (en) 2004-02-09
AU2003254129A8 AU2003254129A8 (en) 2004-02-09

Family

ID=30772984

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2003254129A Abandoned AU2003254129A1 (en) 2002-07-19 2003-07-21 Method and composition for treating and preventing hepatitis b infection and symptoms thereof

Country Status (2)

Country Link
AU (1) AU2003254129A1 (en)
WO (1) WO2004009032A2 (en)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008063996A2 (en) * 2006-11-13 2008-05-29 Functional Genetics, Inc. Therapeutic targeting of escort proteins
CN100586474C (en) * 2006-12-28 2010-02-03 北京炎黄麒麟生物技术开发有限公司 Pharmaceutical composition, kit and application thereof
KR100949310B1 (en) * 2007-11-21 2010-03-23 한국과학기술연구원 Method for measuring interaction between HV capsid protein and surface protein using cell imaging technique and detection method of H proliferation inhibitor
US9963751B2 (en) 2015-11-24 2018-05-08 The Penn State Research Foundation Compositions and methods for identifying agents to reduce hepatitis B virus covalently closed circular DNA
WO2018085208A1 (en) 2016-11-02 2018-05-11 The Research Foundation For The State University Of New York Methods of inhibiting viruses using compositions targeting tsg101-ubiquitin interaction
CN107254000A (en) * 2017-08-09 2017-10-17 芜湖英特菲尔生物制品产业研究院有限公司 A kind of fusion protein being made up of sheep albumin and sheep interferon gamma and preparation method thereof and a kind of restructuring sheep long-acting interferon γ

Also Published As

Publication number Publication date
AU2003254129A8 (en) 2004-02-09
WO2004009032A2 (en) 2004-01-29
WO2004009032A3 (en) 2004-10-21

Similar Documents

Publication Publication Date Title
EP1292603B8 (en) Methods and compositions for treating hepatitis c virus
AU2001245437A1 (en) Lightweight methods and compositions for well treating
AU2003287210A1 (en) Method for treating emissions
AU2002346686A1 (en) Compositions and method for treating hepatitis virus infection
AUPS236902A0 (en) Composition and method for treating hypertension
AU2002323270A1 (en) Composition and method for treating hiv infection
AU2003274537A1 (en) Pyrrolidine derivatives for use in treating heaptitis c virus infection
AU2003225104A1 (en) Composition for reducing malodors and method for using the same
AU2002324753A1 (en) Composition and method for treating viral infection
AU2003239132A1 (en) Methods and compositions for preventing and treating microbial infections
AU2003259202A1 (en) Compositions and methods for treating and preventing infection
AU2003254129A1 (en) Method and composition for treating and preventing hepatitis b infection and symptoms thereof
AU2003238905A1 (en) Surface treating compositions and methods for using same
AU2002322623A1 (en) Methods and compositions for treating diabetes mellitis
AU2002365168A1 (en) Method and composition for treating and preventing hiv infection and aids
AU2003258176A1 (en) Compounds, compositions and methods for treating or preventing pneumovirus infection and associated diseases
AU2003256678A1 (en) Method and composition for treating and preventing hepatitis c infection
AU2003259198A1 (en) Method and composition for treating and preventing influenza infection and symptoms thereof
AU2003237088A1 (en) Compounds, compositions and methods for treating or preventing viral infections and associated diseases
AU2003275069A1 (en) Compositions and methods for preventing infection
AU2003303948A1 (en) Compositions and methods for preventing infection
AU2002327531A1 (en) Therapeutic compositions and methods for treating viral infection
AU2002305700A1 (en) Composition and method for treating cells
AU2003254089A1 (en) Method and composition for treating and preventing herpesvirus infection
AU2003258177A1 (en) Compounds, compositions and methods for treating or preventing pneumovirus infection and associated diseases

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase